Clinical Trial Update: Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating aerosolized sargramostim in combination with immunotherapy for metastatic cutaneous melanoma with lung involvement has been withdrawn…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma
• Melanoma

Drugs mentioned

• Leukine (sargramostim)

Snippet

Sponsor: Mayo Clinic | Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Lung | Phase 1 | Status: WITHDRAWN